Preparing for subsequent entry biologics in dermatology and rheumatology in Canada

Journal of Cutaneous Medicine and Surgery

Volumn 17, Issue 5, 2013, Pages 340-346

  Papp, Kim ^a,b,c,d,e   Bourcier, Marc ^a,b,c,d,e   Ho, Vincent ^a,b,c,d,e   Burke, Karen ^a,b,c,d,e   Haraoui, Boulos ^a,b,c,d,e  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b Dermatology Clinic   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Amgen Canada Inc   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; GENERIC DRUG;

ARTICLE; BIOASSAY; BIOEQUIVALENCE; CANADA; CLINICAL PRACTICE; DERMATOLOGY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE; HUMAN; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOLOGY; DRUG APPROVAL; ORGANIZATION AND MANAGEMENT;

BIOLOGICAL PRODUCTS; CANADA; DERMATOLOGY; DRUG APPROVAL; DRUGS, GENERIC; HUMANS; RHEUMATOLOGY;

EID: 84885801024     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2013.13006     Document Type: Article

References (16)

1. European Medicines Agency. Note for guidance on biotechnological/ biological products subject to charges in their manufacturing process (CPMP/IC/5721/03). Available at: http://www.ema. europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500002805.pdf (accessed January 6, 2013).
2. US Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegula toryInformation/Guidances/ default.htm (accessed January 6, 2013).
3. US Food and Drug Administration. Guidance for industry. Quality considerations in demonstrating biosimilarity to a reference protein product. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/default.htm (accessed January 6, 2013).
4. US Food and Drug Administration. Guidance for industry. Biosimilars: questions and answers regarding implementation of the biologics price competition and innovation act of 2009. Draft guidance. Available at: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/default.htm (accessed January 6, 2013).
5. World Health Organization. Expert Committee on Biological Standardization, Geneva, October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available at: http://www.who.int/biologicals/ areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf (accessed January 6, 2013).
6. Health Canada. Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs). March 5, 2010. Available at: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/seb-pbu/seb-pbu- 2010-eng.php (accessed January 6, 2013).
7. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29:310-2, doi:10.1038/nbt.1839.
8. Chow S, Ju C. Assessing biosimilarity and interchangeability of biosimilar products under the Biolgics Price Competition and Innovation Act. Generics Biosimilars Initiative J 2013;2(1). Available at: http://gabi-journal. net/assessing-biosimilarity-and-interchangeabilityof-biosimilar-products-under- the-biologics-price-competition-andinnovation-act.html (accessed January 21, 2013).
9. Sharma B. Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes. Biotechnol Adv 2007;25:325-31, doi:10.1016/j.biotechadv. 2007.01.007. (Pubitemid 46498674)
10. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005;67:2346-53, doi:10.1111/j.1523-1755.2005.00340.x. (Pubitemid 41623396)
11. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin Endocrinol (Oxf) 1993;38:137-42, doi:10.1111/j.1365-2265.1993.tb00985.x. (Pubitemid 23042721)
12. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-12, doi:10.1002/1531-8249(200011)48:5,706::AID-ANA3.3.0. CO;2-V.
13. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993;16 Suppl 3:155-65. (Pubitemid 23348330)
14. World Health Organization. Guidance on INN. 2007. Available at: http://www.who.int/medicines/services/inn/innquidance/en/index.html (accessed January 12, 2013).
15. World Health Organization. Guidance on INN. Available at: http://www.who.int/medicines/services/inn/innquidance/en/index.html (accessed January 12, 2013).
16. Health Canada. Questions and answers to accompany the final guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs). Available at: http://www.hcsc. gc.ca/dhp-mps/brgtherap/applic-demande/ guides/seb-pbu/01-2010- seb-pbu-qa-qr-eng.php (accessed January 14, 2013).